Interestingly, the expression of P3 and NE in CD34+ CML cells correlated with improved clinical outcomes after treatment with allogeneic stem cell transplantation or IFN therapy, potentially due to improved PR1-specific anti-leukemia effects [22], [23]. The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.